-
Hematopoietic stem cell heterogeneity in non-human primates revealed by five-lineage output bias analysis
Hematopoietic stem cells (HSCs) are pivotal in maintaining blood cell production, and their diversity in lineage output bias significantly influences hematopoietic processes and therapeutic strategies for blood disorders. This study…
-
Machine Learning Prognostic Model for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation: A Revolutionary Approach Towards Personalized Post-Transplant Care
Haploidentical hematopoietic stem cell transplantation (HSCT) has emerged as a pivotal therapeutic intervention for acute leukemia patients. However, post-transplant complications, particularly Epstein-Barr virus (EBV) reactivation, pose significant risks to patient…
-
Professor Erjie Jiang: Poor Prognosis of Acute Graft-versus-Host Disease, Awaiting More New Drugs to Improve Efficacy | The 13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association
Acute graft-versus-host disease (aGVHD) is a severe complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is a major cause of non-relapse mortality in patients with hematologic malignancies. Although treatment options for aGVHD have advanced in recent years, the prognosis remains poor. Recently, the “13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese…
-
Professor Qifa Liu : Clinical Research Should Focus on Methodology of Study Design and Standardization of Registration | The 13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association”
From March 1st to 2nd, 2024, the “13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association,” hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases – Peking University Institute of Hematology, was grandly held in Beijing. Many renowned experts and scholars in the…
-
Professor Ben Lv: Research Progress on Severe Coagulopathy | The 13th National Conference on Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association
Severe coagulopathy poses a serious threat to human life and health, with disseminated intravascular coagulation (DIC) being a common severe coagulopathy characterized by rapid development, dangerous progression, and high mortality. In recent years, Professor Ben Lv from the Second Xiangya Hospital of Central South University has conducted a series of original research studies on the…
-
Hematopoietic Stem Cell Transplantation is Approaching a “New” Breakthrough Moment | The 13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association
In the bright spring of March, various flowers are blooming. The “13th National Hematopoietic Stem Cell Transplantation Academic Conference of the Chinese Medical Association,” hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases – Peking University Institute of Hematology, was grandly held from March 1st to 2nd…
-
Professor Depei Wu: Inheriting, Innovating, and Developing to Promote High-Quality Development in Hematology | The 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association
With the arrival of spring, the 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, hosted by the National Clinical Research Center for Hematologic Diseases and organized by Peking University Institute of Hematology, was grandly held in Beijing from March 1st to 2nd. This conference centered around the basic and clinical…
-
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
In 2022, a groundbreaking study led by Professor Xiaojun Huang from Peking University Institute of Hematology, was published in the prestigious Journal of Hematology & Oncology. The study is titled “Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.” This…
Connecting Medical Expertise through Media